1150-90-9

Usage

Uses

Used in Pharmaceutical Industry:
Estratetraenol is used as a pharmaceutical agent for its hormone-like effects and potential applications in treating various health conditions related to hormone imbalances. Its ability to mimic the actions of estrogen makes it a valuable compound for research and development in the pharmaceutical sector.
Used in Cosmetics Industry:
In the cosmetics industry, Estratetraenol is used as an ingredient in various skincare and beauty products due to its hormone-like properties. It is believed to help with skin rejuvenation, reducing the signs of aging, and maintaining overall skin health.
Used in Research and Development:
Estratetraenol is used as a research compound for studying the effects of hormones on the human body. Its pheromone activities make it an interesting subject for research in the fields of biology, endocrinology, and neuroscience.
Used in Agriculture:
Estratetraenol can be used in the agricultural industry as a pheromone to control pest populations. Its ability to attract or repel certain insects can be harnessed to develop more targeted and environmentally friendly pest control strategies.
Used in Environmental Science:
In environmental science, Estratetraenol can be used to study the effects of hormones on wildlife and ecosystems. Understanding how these compounds interact with the environment can help in developing strategies to mitigate the impact of hormonal pollutants on wildlife and their habitats.

InChI:InChI=1/C18H22O/c1-18-9-2-3-17(18)16-6-4-12-11-13(19)5-7-14(12)15(16)8-10-18/h2,5,7,9,11,15-17,19H,3-4,6,8,10H2,1H3/t15-,16-,17+,18+/m1/s1

Upstream product

• 50-28-2 estradiol 
• 53-16-7 Estrone 
• 23880-57-1 (8S,9S,13R,14S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15-octahydro-6H-cyclopenta[a]phenanthrene 
• 55105-93-6 estrone p-toluenesulfonylhydrazone 

Downstream Products

• 472-56-0 Estroxide 
• 1316291-21-0 (8R,9S,13S,14S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-16,17-diol 
• 23880-57-1 (8S,9S,13R,14S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15-octahydro-6H-cyclopenta[a]phenanthrene 

Relevant academic research and scientific papers

A pharmaceutical composition containing 2-hydroxy-7-methyl octahydrophenanthrene derivative as an estrogen receptor ligand or a pharmaceutically acceptable salt thereof as an effective component

Provided are a compound represented by chemical formulas I and II, or a pharmaceutically acceptable ester, amide, or carbamate salt thereof; and a solvent compound comprising a solvent compound of the ester, amide, or carbamate salt thereof. In addition, provided are use of the compound in treating or preventing diseases or disorders related to activation of an estrogen receptor, and a pharmaceutical composition comprising the compound. In chemical formulas I and II, definitions of R_1, R_2, R_3, and R_4 are the same as those in the specification.COPYRIGHT KIPO 2016

Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices

A method of increasing alertness in an individual by administering an effective amount of an alertness-increasing vomeropherin to the individual; and an alarm device that, when activated, emits an alertness-increasing vomeropherin. The method and device are especially useful in increasing alertness in individuals who are not readily responsive to usual external stimuli.

ESTRENE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Estrene steroid, or a pharmaceutical composition containing an Estrene steroid, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

Steroids as neurochemical stimulators of the VNO to alleviate pain

The invention relates to a method of alleviating pain. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety

The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia

The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

Steroids as neurochemical initiators of change in human blood levels of LH

The invention relates to a method of altering the blood levels of LH or FSH in an individual. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

Estrenes for inducing hypothalamic effects

The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

Fragrance compositions and other compositions which contain human pheromones

The invention concerns novel, non-therapeutic fragrance compositions and other compositions containing an odorant and a naturally occurring human pheromone. The invention also concerns fragrance compositions containing mixtures of naturally occurring human pheromones. The human pheromones disclosed are steroids which desirably belong to two distinct chemical classes: 16-Androstenes and Estrenes.